Characterization of novel TMEM173 mutation with additive IFIH1 risk allele

TMEM173 encodes for STING that is a transmembrane protein activated by pathogen or self-derived cytosolic nucleic acids causing its translocation from ER to Golgi, and further to vesicles. Monogenic STING gain-of-function mutations cause early-onset type I interferonopathy, with disease presentation ranging from fatal vasculopathy to mild chilblain lupus. Molecular mechanisms causing the poor phenotypegenotype correlation are presently unclear. Here we report a novel gain-of-function G207E STING mutation causing a distinct phenotype with alopecia, photosensitivity, thyroid dysfunction, and STING-associated vasculopathy with onset in infancy (SAVI) -features; livedo reticularis, nasal septum perforation, facial erythema, bacterial infections and skin vasculitis. Single residue polymorphisms in TMEM173 and an IFIH1 T946 risk allele modify disease presentation in the affected multigeneration family, explaining the varying clinical phenotypes. The G207E mutation causes constitutive activation of inflammation-related pathways in HEK cells, as well as aberrant interferon signature and inflammasome activation in patient PBMCs. Protein-protein interactions further propose impaired cellular trafficking of G207E mutant STING. These findings reveal the molecular landscape of STING and highlight the complex additive effects on the phenotype. BRIEF SUMMARY Novel gain-of-function mutation in TMEM173, associated with single residue polymorphisms in TMEM173 and IFIH1, causes a distinct clinical phenotype with some shared features of SAVI.

[1]  S. Masters,et al.  A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy , 2018, Front. Immunol..

[2]  J. Lupski,et al.  Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING. , 2018, Cell reports.

[3]  Xiaonan Liu,et al.  An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations , 2018, Nature Communications.

[4]  Nan Yan,et al.  Trafficking-Mediated STING Degradation Requires Sorting to Acidified Endolysosomes and Can Be Targeted to Enhance Anti-tumor Response. , 2017, Cell reports.

[5]  Avani A. Pendse,et al.  A noncanonical function of cGAMP in inflammasome priming and activation , 2017, The Journal of experimental medicine.

[6]  Jonathan L. Schmid-Burgk,et al.  The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3 , 2017, Cell.

[7]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic Acids Res..

[8]  Nan Yan,et al.  STING-associated vasculopathy develops independently of IRF3 in mice , 2017, The Journal of experimental medicine.

[9]  F. Rieux-Laucat,et al.  Disease‐associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling , 2017, The Journal of allergy and clinical immunology.

[10]  E. Kiss-Toth,et al.  Regulating STING in health and disease , 2017, Journal of Inflammation.

[11]  F. Rieux-Laucat,et al.  Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes , 2017, The Journal of experimental medicine.

[12]  D. Liggitt,et al.  The A946T variant IFIH1 RNA sensor mediates an interferon program that limits viral infection but increases the risk for autoimmunity , 2017, Nature Immunology.

[13]  Tom L. Blundell,et al.  SDM: a server for predicting effects of mutations on protein stability , 2017, Nucleic Acids Res..

[14]  S. Mustjoki,et al.  Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry , 2017, Human mutation.

[15]  C. Bodemer,et al.  Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease , 2016, Journal of Clinical Immunology.

[16]  G. Núñez,et al.  Mechanism and Regulation of NLRP3 Inflammasome Activation. , 2016, Trends in biochemical sciences.

[17]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[18]  David S. Goodsell,et al.  The RCSB protein data bank: integrative view of protein, gene and 3D structural information , 2016, Nucleic Acids Res..

[19]  P. Kessler,et al.  STING Requires the Adaptor TRIF to Trigger Innate Immune Responses to Microbial Infection. , 2016, Cell host & microbe.

[20]  J. Aróstegui,et al.  From Primary Immunodeficiency to Autoimmunity: How Extreme Situations Highlight the Main Genetic Factors Involved in Autoimmune Disease , 2016 .

[21]  F. Rieux-Laucat,et al.  Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation). , 2016, Chest.

[22]  C. Fiehn,et al.  Familial chilblain lupus due to a gain-of-function mutation in STING , 2016, Annals of the rheumatic diseases.

[23]  H. Hoffman,et al.  The role of the inflammasome in patients with autoinflammatory diseases. , 2016, The Journal of allergy and clinical immunology.

[24]  G. Barber,et al.  Activation of STING requires palmitoylation at the Golgi , 2016, Nature Communications.

[25]  Jonathan L. Schmid-Burgk,et al.  Human Monocytes Engage an Alternative Inflammasome Pathway. , 2016, Immunity.

[26]  M. Diamond,et al.  S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3 , 2016, Nature Immunology.

[27]  Xiangshi Tan,et al.  Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.

[28]  C. Bodemer,et al.  Unusual cutaneous features associated with a heterozygous gain‐of‐function mutation in IFIH1: overlap between Aicardi‐Goutières and Singleton‐Merten syndromes , 2015, The British journal of dermatology.

[29]  Nan Yan,et al.  STING Activation by Translocation from the ER Is Associated with Infection and Autoinflammatory Disease. , 2015, Cell host & microbe.

[30]  F. Rieux-Laucat,et al.  Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Mimic of Childhood Granulomatosis With Polyangiitis. , 2015, JAMA dermatology.

[31]  Y. Crow,et al.  Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.

[32]  Mark S. Anderson,et al.  COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis , 2015, Nature Genetics.

[33]  P. Woo,et al.  Stimulator of Interferon Genes–Associated Vasculitis of Infancy , 2015, Arthritis & rheumatology.

[34]  R. Hennekam,et al.  A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. , 2015, American journal of human genetics.

[35]  J. Kere,et al.  Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. , 2015, Blood.

[36]  T. Molina,et al.  Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. , 2014, The Journal of clinical investigation.

[37]  Ha Won Kim,et al.  Activated STING in a vascular and pulmonary syndrome. , 2014, The New England journal of medicine.

[38]  L. Jackson Structure and mechanism of COPI vesicle biogenesis. , 2014, Current opinion in cell biology.

[39]  O. Ohara,et al.  Aicardi-Goutières syndrome is caused by IFIH1 mutations. , 2014, American journal of human genetics.

[40]  M. Crow Type I Interferon in the Pathogenesis of Lupus , 2014, The Journal of Immunology.

[41]  L. Lagae,et al.  Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling , 2014, Nature Genetics.

[42]  T. Noda,et al.  Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. , 2014, Immunity.

[43]  S. Mustjoki,et al.  Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy , 2014, PloS one.

[44]  V. Brendel,et al.  Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides , 2013, PloS one.

[45]  Roger A. Jones,et al.  Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA , 2013, Cell.

[46]  Zhijian J. Chen,et al.  Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. , 2013, Molecules and Cells.

[47]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[48]  Scott M. Williams,et al.  Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production , 2013, PLoS genetics.

[49]  R. Vance,et al.  STING and the innate immune response to nucleic acids in the cytosol , 2012, Nature Immunology.

[50]  L. Stein,et al.  Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome , 2012, Cancers.

[51]  Yuan Tian,et al.  Cyclic di-GMP sensing via the innate immune signaling protein STING. , 2012, Molecular cell.

[52]  X. Su,et al.  The structural basis for the sensing and binding of cyclic di-GMP by STING , 2012, Nature Structural &Molecular Biology.

[53]  Bodo Grimbacher,et al.  Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. , 2012, American journal of human genetics.

[54]  Brian Burke,et al.  A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells , 2012, The Journal of cell biology.

[55]  Zhijian J. Chen,et al.  STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway , 2012, Science Signaling.

[56]  Y. Crow Type I interferonopathies: a novel set of inborn errors of immunity , 2011, Annals of the New York Academy of Sciences.

[57]  Yoshihiro Hayakawa,et al.  STING is a direct innate immune sensor of cyclic-di-GMP , 2011, Nature.

[58]  M. Jolly,et al.  Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN-α and Serologic Autoimmunity in Lupus Patients , 2011, The Journal of Immunology.

[59]  Meghana Kulkarni Digital multiplexed gene expression analysis using the NanoString nCounter system. , 2011, Current protocols in molecular biology.

[60]  Sky W. Brubaker,et al.  The N-Ethyl-N-Nitrosourea-Induced Goldenticket Mouse Mutant Reveals an Essential Function of Sting in the In Vivo Interferon Response to Listeria monocytogenes and Cyclic Dinucleotides , 2010, Infection and Immunity.

[61]  Yihong Yao,et al.  Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus , 2009, Human genomics and proteomics : HGP.

[62]  R. Aebersold,et al.  An integrated workflow for charting the human interaction proteome: insights into the PP2A system , 2009, Molecular systems biology.

[63]  R. Xavier,et al.  The tumour suppressor CYLD is a negative regulator of RIG‐I‐mediated antiviral response , 2008, EMBO reports.

[64]  Francisco M De La Vega,et al.  A second-generation combined linkage physical map of the human genome. , 2007, Genome research.

[65]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[66]  G. Bjørkøy,et al.  p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death , 2005, The Journal of cell biology.

[67]  A. Rao Faculty Opinions recommendation of CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. , 2003 .

[68]  A. Ashworth,et al.  CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members , 2003, Nature.

[69]  G. Courtois,et al.  The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination , 2003, Nature.

[70]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[71]  L. Orci,et al.  ADP-Ribosylation factor is a subunit of the coat of Golgi-derived COP-coated vesicles: A novel role for a GTP-binding protein , 1991, Cell.

[72]  J. Rothman,et al.  'Coatomer': a cytosolic protein complex containing subunits of non-clathrin-coated Golgi transport vesicles , 1991, Nature.

[73]  S. Özen,et al.  Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. , 2016, Journal of the American Academy of Dermatology.

[74]  G. Abecasis,et al.  Merlin—rapid analysis of dense genetic maps using sparse gene flow trees , 2002, Nature Genetics.